Buflomedil

  • Email
  • Help

The European Medicines Agency has completed a review of the safety and effectiveness of buflomedil-containing medicines, both oral and injectable, due to serious side effects seen with buflomedil. The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of buflomedil do not outweigh its risks, and has recommended that all marketing authorisations for medicines containing buflomedil should be suspended throughout the European Union (EU).

What is buflomedil?

Buflomedil is a vasoactive agent, a medicine which has an effect on blood circulation. Buflomedil increases the blood flow to the brain and other parts of the body by widening the blood vessels. It is used to treat the symptoms of peripheral arterial occlusive disease (PAOD), a condition where the body’s large arteries become obstructed causing symptoms such as pain and weakness, particularly in the legs. Buflomedil is used in patients with stage II PAOD, which means that they experience severe pain when walking relatively short distances.

Buflomedil-containing medicines have been authorised in the EU since the 1970s via national procedures. Buflomedil is authorised in Austria, Belgium, Cyprus, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Poland, Portugal and Spain, under the invented name Loftyl and other trade names. Buflomedil is available in the form of tablets, an oral solution or a solution for injection.

Why was buflomedil reviewed?

In February 2011, the French medicines regulatory agency suspended the marketing authorisations for buflomedil-containing medicines because of serious and sometimes fatal side effects seen with these medicines. These included neurological disorders such as convulsions and status epilepticus (a dangerous condition where the brain is in a persistent state of seizure), and cardiac disorders such as accelerated heart rate and cardiac arrest. These side effects mainly occurred in elderly patients or in patients with kidney problems who did not receive the appropriately reduced dose and whose kidney function was not suitably monitored. Buflomedil can build up in the body and there is only a small difference between the treating dose and the dose that can harm certain patients, such as those with kidney problems. Patients with PAOD are likely to have kidney problems due to the nature of the condition.

Measures to minimise the risks with buflomedil had already been taken in some of the Member States where the medicine is marketed. These included changes to the packaging and product information, recommendations on adjusting the dose for patients with kidney problems and restrictions on the medicines’ use in certain patients (for instance patients with epilepsy). France had previously taken such measures in 1998 and 2006, but concluded in February 2011 that these had not been sufficient to prevent serious side effects from occurring in France.

As required by Article 107, France informed the CHMP of its latest action to suspend the marketing authorisations in France, so that the Committee could prepare an opinion on whether the marketing authorisations for products containing buflomedil should be maintained, changed, suspended or withdrawn across the EU.

Which data has the CHMP reviewed?

The CHMP considered the benefit-risk assessments previously carried out, including by France in 2010-2011, as well as information requested from the companies that market buflomedil-containing medicines in the EU. This included data from clinical trials with buflomedil, post-marketing surveillance and the published literature, as well as from poison control centres in Europe on cases of severe poisoning with buflomedil.

What are the conclusions of the CHMP?

The CHMP noted that there was a risk of serious neurological and cardiac side effects in patients when buflomedil is used normally, due to the small difference between the treating dose and the dose that can harm elderly patients or people with certain conditions such as kidney problems, which are common in patients with PAOD. In spite of measures put in place by regulatory authorities to minimise the risks, serious side effects continue to be reported. The CHMP also noted that the medicine had only been shown to have a limited benefit for patients, measured in terms of walking distance, and that the studies also had a number of methodological weaknesses.

Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of buflomedil-containing medicines do not outweigh their risks, and recommended that all marketing authorisations for medicines containing buflomedil should be suspended throughout the EU.

What are the recommendations for patients and prescribers?
  • Patients who have any questions should speak to their doctor or pharmacist.
  • Doctors should stop prescribing buflomedil and consider alternative treatment options. These include managing underlying health problems which can increase the risk of PAOD, such as diabetes, high cholesterol, high blood pressure as well as smoking.
  • Patients currently using buflomedil-containing medicines should speak to their doctor to review their treatment.

The European Commission issued a decision on 13 February 2012.

Name Language First published Last updated
Questions and answers on the suspension of buflomedil-containing medicines BG = bălgarski 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines ES = español 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines CS = čeština 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines DA = dansk 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines DE = Deutsch 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines ET = eesti keel 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines EL = elliniká 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines EN = English 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines FR = français 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines IT = italiano 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines LV = latviešu valoda 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines LT = lietuvių kalba 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines HU = magyar 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines MT = Malti 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines NL = Nederlands 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines PL = polski 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines PT = português 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines RO = română 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines SK = slovenčina 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines SL = slovenščina 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines FI = suomi 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines SV = svenska 2011-11-17 2012-06-13

Key facts

Approved nameBuflomedil
International non-proprietary name (INN) or common name

buflomedil

Associated names
Classvasoactive agent
Reference numberEMEA/H/A-107/1293
TypeArticle 107 procedures (prior to July 2012)

This type of procedure was triggered when a Member State varied, suspended or revoked the marketing authorisation for a medicine in its territory because of a safety issue. This procedure is no longer applicable and has been replaced by Article 107i.

StatusEuropean Commission final decision
Opinion date17/11/2011

All documents

Name Language First published Last updated
Buflomedil - Article 107 referral - Assessment report (English only) 2012-06-13  
Questions and answers on the suspension of buflomedil-containing medicines BG = bălgarski 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines ES = español 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines CS = čeština 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines DA = dansk 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines DE = Deutsch 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines ET = eesti keel 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines EL = elliniká 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines EN = English 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines FR = français 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines IT = italiano 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines LV = latviešu valoda 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines LT = lietuvių kalba 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines HU = magyar 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines MT = Malti 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines NL = Nederlands 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines PL = polski 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines PT = português 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines RO = română 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines SK = slovenčina 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines SL = slovenščina 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines FI = suomi 2011-11-17 2012-06-13
Questions and answers on the suspension of buflomedil-containing medicines SV = svenska 2011-11-17 2012-06-13
Buflomedil - Article 107 referral - Annex I BG = bălgarski 2012-06-13  
Buflomedil - Article 107 referral - Annex I ES = español 2012-06-13  
Buflomedil - Article 107 referral - Annex I CS = čeština 2012-06-13  
Buflomedil - Article 107 referral - Annex I DA = dansk 2012-06-13  
Buflomedil - Article 107 referral - Annex I DE = Deutsch 2012-06-13  
Buflomedil - Article 107 referral - Annex I ET = eesti keel 2012-06-13  
Buflomedil - Article 107 referral - Annex I EL = elliniká 2012-06-13  
Buflomedil - Article 107 referral - Annex I EN = English 2012-06-13  
Buflomedil - Article 107 referral - Annex I FR = français 2012-06-13  
Buflomedil - Article 107 referral - Annex I IT = italiano 2012-06-13  
Buflomedil - Article 107 referral - Annex I LV = latviešu valoda 2012-06-13  
Buflomedil - Article 107 referral - Annex I LT = lietuvių kalba 2012-06-13  
Buflomedil - Article 107 referral - Annex I HU = magyar 2012-06-13  
Buflomedil - Article 107 referral - Annex I MT = Malti 2012-06-13  
Buflomedil - Article 107 referral - Annex I NL = Nederlands 2012-06-13  
Buflomedil - Article 107 referral - Annex I PL = polski 2012-06-13  
Buflomedil - Article 107 referral - Annex I PT = português 2012-06-13  
Buflomedil - Article 107 referral - Annex I RO = română 2012-06-13  
Buflomedil - Article 107 referral - Annex I SK = slovenčina 2012-06-13  
Buflomedil - Article 107 referral - Annex I SL = slovenščina 2012-06-13  
Buflomedil - Article 107 referral - Annex I FI = suomi 2012-06-13  
Buflomedil - Article 107 referral - Annex I SV = svenska 2012-06-13  
Buflomedil - Article 107 referral - Annex II BG = bălgarski 2012-06-13  
Buflomedil - Article 107 referral - Annex II ES = español 2012-06-13  
Buflomedil - Article 107 referral - Annex II CS = čeština 2012-06-13  
Buflomedil - Article 107 referral - Annex II DA = dansk 2012-06-13  
Buflomedil - Article 107 referral - Annex II DE = Deutsch 2012-06-13  
Buflomedil - Article 107 referral - Annex II ET = eesti keel 2012-06-13  
Buflomedil - Article 107 referral - Annex II EL = elliniká 2012-06-13  
Buflomedil - Article 107 referral - Annex II EN = English 2012-06-13  
Buflomedil - Article 107 referral - Annex II FR = français 2012-06-13  
Buflomedil - Article 107 referral - Annex II IT = italiano 2012-06-13  
Buflomedil - Article 107 referral - Annex II LV = latviešu valoda 2012-06-13  
Buflomedil - Article 107 referral - Annex II LT = lietuvių kalba 2012-06-13  
Buflomedil - Article 107 referral - Annex II HU = magyar 2012-06-13  
Buflomedil - Article 107 referral - Annex II MT = Malti 2012-06-13  
Buflomedil - Article 107 referral - Annex II NL = Nederlands 2012-06-13  
Buflomedil - Article 107 referral - Annex II PL = polski 2012-06-13  
Buflomedil - Article 107 referral - Annex II PT = português 2012-06-13  
Buflomedil - Article 107 referral - Annex II RO = română 2012-06-13  
Buflomedil - Article 107 referral - Annex II SK = slovenčina 2012-06-13  
Buflomedil - Article 107 referral - Annex II SL = slovenščina 2012-06-13  
Buflomedil - Article 107 referral - Annex II FI = suomi 2012-06-13  
Buflomedil - Article 107 referral - Annex II SV = svenska 2012-06-13  
Buflomedil - Article 107 referral - Annex III BG = bălgarski 2012-06-13  
Buflomedil - Article 107 referral - Annex III ES = español 2012-06-13  
Buflomedil - Article 107 referral - Annex III CS = čeština 2012-06-13  
Buflomedil - Article 107 referral - Annex III DA = dansk 2012-06-13  
Buflomedil - Article 107 referral - Annex III DE = Deutsch 2012-06-13  
Buflomedil - Article 107 referral - Annex III ET = eesti keel 2012-06-13  
Buflomedil - Article 107 referral - Annex III EL = elliniká 2012-06-13  
Buflomedil - Article 107 referral - Annex III EN = English 2012-06-13  
Buflomedil - Article 107 referral - Annex III FR = français 2012-06-13  
Buflomedil - Article 107 referral - Annex III IT = italiano 2012-06-13  
Buflomedil - Article 107 referral - Annex III LV = latviešu valoda 2012-06-13  
Buflomedil - Article 107 referral - Annex III LT = lietuvių kalba 2012-06-13  
Buflomedil - Article 107 referral - Annex III HU = magyar 2012-06-13  
Buflomedil - Article 107 referral - Annex III MT = Malti 2012-06-13  
Buflomedil - Article 107 referral - Annex III NL = Nederlands 2012-06-13  
Buflomedil - Article 107 referral - Annex III PL = polski 2012-06-13  
Buflomedil - Article 107 referral - Annex III PT = português 2012-06-13  
Buflomedil - Article 107 referral - Annex III RO = română 2012-06-13  
Buflomedil - Article 107 referral - Annex III SK = slovenčina 2012-06-13  
Buflomedil - Article 107 referral - Annex III SL = slovenščina 2012-06-13  
Buflomedil - Article 107 referral - Annex III FI = suomi 2012-06-13  
Buflomedil - Article 107 referral - Annex III SV = svenska 2012-06-13  
Questions and answers on the suspension of oral buflomedil-containing medicines (English only) 2011-05-20  

Document description

  • Questions and answers (Q&A) - easy-to-understand summary of key issues and Committee conclusions
  • Summary of Opinion - contains the CHMP opinion of the referred medicine(s)
  • List of the medicines affected by the referral (Annex I)
  • Scientific conclusions of the Committee (Annex II)

The following two documents are sometimes available:

  • Changes to the summary of product characteristics, labeling or package leaflet (also known as Annex III) - available when changes have been recommended by the Committee
  • Conditions of the marketing authorisation (also known as Annex IV) - available when the Committee recommends measures to be taken for the marketing authorisation(s) such as safety measures or extra studies

Current status:
European Commission final decision

More information on buflomedil